OTCMKTS:MEDGF - Medacta Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$123.50
+0.30 (1.20%)

This chart shows the closing price for MEDGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medacta Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDGF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Medacta Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $123.50.

This chart shows the closing price for MEDGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Medacta Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/30/2021UBS GroupReiterated RatingNeutral
6/9/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Medacta Group logo
Medacta Group SA develops, manufactures, and distributes orthopedic and spinal surgery medical devices in Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Read More

Today's Range

Now: $123.50
Low: $123.50
High: $123.50

50 Day Range

MA: $123.50
Low: $123.50
High: $123.50

52 Week Range

Now: $123.50
Low: $123.50
High: $123.50

Volume

100 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medacta Group?

The following Wall Street research analysts have issued stock ratings on Medacta Group in the last twelve months: Credit Suisse Group AG, and UBS Group AG.
View the latest analyst ratings for MEDGF.

What is the current price target for Medacta Group?

0 Wall Street analysts have set twelve-month price targets for Medacta Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medacta Group in the next year.
View the latest price targets for MEDGF.

What is the current consensus analyst rating for Medacta Group?

Medacta Group currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDGF, but not buy more shares or sell existing shares.
View the latest ratings for MEDGF.

How do I contact Medacta Group's investor relations team?

Medacta Group's physical mailing address is Strada Regina, Castel San Pietro, Ticino (Ticiono). The company's listed phone number is 41 91 696 60 60. The official website for Medacta Group is www.medacta.com.